Almirall, S.A. LBTSF
Set alert
15.35 USD +5.60 +57.44%
As of Feb 9, 9:34 AM ET
15.35 Day range 15.35
13.36 52-week range 15.47
- YTD
- -0.78%
- 1 year
- +70.37%
- Open
- 15.35
- Prev close
- 9.75
- Mkt cap
- 3.34B
- Vol
- 100
- Avg vol
- 0
- EPS
- 0.25
- P/E
- 61.40
More statistics
- Low
- 15.35
- High
- 15.35
- Earnings
- Nov 9, 2026
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate 0.1498.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | 0.1498 | — | — | — |
| Jul 24, 2026 | Jun 30, 2026 | 0.1485 | 0.1484 | 0.00 | -0.07% |
| May 11, 2026 | Mar 31, 2026 | 0.104 | 0.08088 | -0.02 | -22.23% |
| Feb 23, 2026 | Dec 31, 2025 | — | 0.1057 | — | — |
| Nov 10, 2025 | Sep 30, 2025 | — | 0.06877 | — | — |
| Jul 25, 2025 | Jun 30, 2025 | — | 0.02749 | — | — |
News
- Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026
- Almirall, S.A. (ALMRY) Q2 2026 Earnings Call Transcript
- Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older
- Almirall, S.A. (ALMRY) Q1 2026 Earnings Call Transcript
- Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
- AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
- Almirall, S.A. (LBTSF) Q4 2025 Earnings Call Transcript
- Almirall, S.A. (LBTSF) Presents at 44th Annual J.P.
- Almirall, S.A. (LBTSF) Q3 2025 Earnings Call Transcript
- Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Your note
Sign in to keep a note on LBTSF — it syncs with the Stock Master app.